azacitidine has been researched along with Anemia, Refractory, with Excess of Blasts in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (11.76) | 18.2507 |
| 2000's | 3 (8.82) | 29.6817 |
| 2010's | 22 (64.71) | 24.3611 |
| 2020's | 5 (14.71) | 2.80 |
| Authors | Studies |
|---|---|
| Czabak, O; Hus, M; Juda, A; Kozioł, M; Majowicz, D; Sokołowska, B; Soroka-Wojtaszko, M; Wąsik-Szczepanek, E | 1 |
| Chiba, S; Dobashi, N; Handa, H; Harada, H; Hata, T; Honda, S; Horiike, S; Ichikawa, M; Ishiyama, K; Ito, Y; Iyama, S; Kiguchi, T; Kiyoi, H; Kurokawa, T; Maeda, T; Matsuda, M; Matsumura, I; Miyazaki, Y; Moriuchi, Y; Naoe, T; Ohtake, S; Sato, S; Suzuki, T; Suzushima, H; Taguchi, J; Tomita, A; Usuki, K; Yamauchi, T; Yokota, K | 1 |
| Bewersdorf, JP; Davidoff, AJ; Gore, SD; Hu, X; Huntington, SF; Ma, X; Podoltsev, NA; Wang, R; Zeidan, AM | 1 |
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Corman, S; Hill, K; Joshi, N; Kale, H; Wert, T; Zeidan, AM | 1 |
| Guo, R; Han, HH; Jiang, ZX; Liu, YF; Sun, H; Wang, M | 1 |
| Cevreska, L; Dimovski, AJ; Ivanovski, M; Matevska-Geshovska, N; Noveski, P; Panovska-Stavridis, I; Pivkova-Veljanovska, A; Plaseska-Karanfilska, D; Popova-Labaceska, M; Trajkova, S | 1 |
| Aisa, Y; Fujita, Y; Ito, C; Masuda, K; Mori, T; Nakazato, T; Osada, Y | 1 |
| Guinea de Castro, JM; Moreno de Gusmão, B; Oiartzabal, I; Perez-Persona, E | 1 |
| Brice, J; Defilipp, Z; Lister, J; Wasko, MC | 1 |
| Fernández-Sojo, J; Oliveras Vilà, T; Ribera, JM; Vives, S | 1 |
| Bredeson, C; McCurdy, A; Sabloff, M; Sheppard, D; Shier, L; Xu, Z | 1 |
| Aul, C; Baron, F; Becker, H; de Witte, T; Fiaccadori, V; Ganser, A; Germing, U; Giagounidis, A; Hagemeijer, A; Labar, B; Lübbert, M; Muus, P; Pflüger, KH; Platzbecker, U; Rüter, BH; Salih, HR; Schaefer, HE; Selleslag, D; Suciu, S; Wijermans, PW | 1 |
| Kalayoğlu Beşışık, S; Turan Erkek, E | 1 |
| Atagunduz, IK; Avsar, E; Deveci, B; Ferhanoglu, B; Geduk, A; Kara, O; Kurtoglu, E; Mehtap, O; Ozturk, E; Salim, O; Tiftik, EN; Tombak, A; Toptas, T; Tuglular, TF; Undar, L; Yucel, OK | 1 |
| Abel, GA; Davidoff, AJ; Gore, SD; Gross, CP; Hajime, U; Hu, X; Huntington, SF; Long, JB; Ma, X; Podoltsev, NA; Prebet, T; Wang, R; Zeidan, AM | 1 |
| Fang, LW; Hu, NB; Li, B; Luo, XP; Pan, LJ; Qin, TJ; Qu, SQ; Xiao, ZJ; Xu, ZF; Zhang, HL; Zhang, Y | 1 |
| Hu, C; Jin, J; Lin, P; Lou, Y; Luo, Y; Ma, L; Mai, W; Mei, C; Meng, H; Qian, J; Qian, W; Ren, Y; Tong, H; Wei, J; Xie, L; Xu, G; Xu, W; Ye, L; Ye, X; Zhou, X | 1 |
| Blum, S; Gattermann, N; Germing, U; Haas, R; Habersang, K; Kuendgen, A; Möller, I | 1 |
| Backstrom, J; Beach, CL; Fenaux, P; Gore, SD; Hellström-Lindberg, E; List, A; Mufti, GJ; Santini, V; Seymour, JF; Silverman, LR | 1 |
| Afable, M; Englehaupt, R; List, AF; Maciejewski, JP; O'Keefe, C; Paulic, K; Sekeres, MA | 1 |
| Berz, D; Cassidy, HM; Connell, NT; Winer, ES | 1 |
| Auffret, M; Bibault, JE; Cambier, N; Lemahieu, JM; Quesnel, B; Rose, C | 1 |
| Delgado, RG; Diez Campelo, M; Molias, AC; Sanchez, JF | 1 |
| Chae, YS; Kang, BW; Kim, JG; Lee, SJ; Lee, YJ; Moon, JH; Sohn, SK; Suh, JS | 1 |
| Alimena, G; Breccia, M; Loglisci, G; Mancini, M; Petrucci, L; Salaroli, A; Serrao, A | 1 |
| Bao, L; Huang, XJ | 1 |
| Bernal, T; Gutiérrez-Fernández, A; Moncada-Pazos, A; Soria-Valles, C | 1 |
| Creamer, JD; du Vivier, AW; Ho, A; Mufti, GJ; Raj, K; Salisbury, JR | 1 |
| Friedman, HD; Landaw, SA; Litam, PP | 1 |
| Alter, BP; Carey, RW; Cornell, CJ; Davis, RB; Demakos, EP; Ellison, RR; Holland, JF; Schiffer, C; Silverman, LR; Weinberg, RS | 1 |
| Babare, R; De Angelis, V; Gattei, V; Lo Re, G; Marotta, G; Monfardini, S; Pinto, A; Sardeo, G; Zagonel, V | 1 |
| Huijgens, PC; Krulder, JW; Neve, P; Wijermans, PW | 1 |
| Andre, M; Bosly, A; Ferrant, A; Kunzmann, R; Lübbert, M; Ravoet, C; Verhoef, G; Wijermans, P | 1 |
1 review(s) available for azacitidine and Anemia, Refractory, with Excess of Blasts
| Article | Year |
|---|---|
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
6 trial(s) available for azacitidine and Anemia, Refractory, with Excess of Blasts
| Article | Year |
|---|---|
Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial.
Topics: Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; Humans; Myelodysplastic Syndromes | 2022 |
Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS St
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Decitabine; Disease-Free Survival; Female; Humans; Male; Middle Aged; Survival Rate | 2015 |
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; Disease Management; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2010 |
Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Humans; Lenalidomide; Male; Middle Aged; Risk Factors; Thalidomide | 2011 |
Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Azacitidine; Blood Transfusion; Erythrocyte Transfusion; Erythroid Precursor Cells; Female; Hematopoiesis; Humans; Infusions, Intravenous; Male | 1993 |
5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antigens, CD; Antigens, CD34; Azacitidine; Bone Marrow; Decitabine; Female; Humans; Male; Middle Aged; Remission Induction | 1993 |
27 other study(ies) available for azacitidine and Anemia, Refractory, with Excess of Blasts
| Article | Year |
|---|---|
RAEB II type of myelodysplastic syndrome associated with axillary abscesses - Case Report.
Topics: Abscess; Anemia, Refractory, with Excess of Blasts; Azacitidine; Humans; Myelodysplastic Syndromes | 2021 |
Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Humans; Medicare; Myelodysplastic Syndromes; Propensity Score; Retrospective Studies; United States | 2020 |
Under-use of Hypomethylating Agents in Patients With Higher-risk Myelodysplastic Syndrome in the United States: A Large Population-based Analysis.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Drug Utilization; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Retrospective Studies; SEER Program; United States | 2021 |
[Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2017 |
Moleculary Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidne.
Topics: Anemia, Refractory, with Excess of Blasts; Azacitidine; Bone Marrow Examination; Chromosomes, Human, Y; Cytogenetic Analysis; DNA Modification Methylases; Drug Administration Schedule; Enzyme Inhibitors; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Predictive Value of Tests; Remission Induction; Treatment Outcome | 2017 |
A rare case of an acquired factor V inhibitor in a patient with myelodysplastic syndrome during azacitidine treatment.
Topics: Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Autoimmune Diseases; Azacitidine; Early Diagnosis; Factor V; Factor V Deficiency; Gingival Hemorrhage; Humans; Immunosuppressive Agents; Male; Partial Thromboplastin Time; Prednisone; Prothrombin Time | 2018 |
[Transfusional independence in a patient with refractory anemia with excess blasts-2 refractory to 5-azacitidine treated with deferasirox and colony stimulating factors].
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Benzoates; Blood Transfusion; Chelation Therapy; Combined Modality Therapy; Deferasirox; Disease Progression; Drug Resistance; Epoetin Alfa; Erythropoietin; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Iron; Iron Chelating Agents; Leukemia, Myeloid, Acute; Male; Recombinant Proteins; Triazoles | 2014 |
Myelodysplastic syndrome presenting as sarcoidosis.
Topics: Administration, Oral; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; Biopsy; Bone Marrow Examination; Fatal Outcome; Female; Granuloma; Humans; Iritis; Middle Aged; Peripheral Blood Stem Cell Transplantation; Sarcoidosis; Sarcoidosis, Pulmonary; Steroids; Time Factors; Treatment Outcome | 2013 |
[Exudative pericardial effusion and oligoarthritis in a patient newly diagnosed with myelodysplastic syndrome].
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Azacitidine; Cytarabine; Disease Progression; Etoposide; Fatal Outcome; Hepatomegaly; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Serositis | 2014 |
Systemic mastocytosis emerging after azacitidine treatment of refractory anaemia with excess blasts type 2.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; Fatal Outcome; Humans; Male; Mastocytosis, Systemic | 2014 |
An Unexpected Innocent Complication Associated with Azacitidine Treatment of Myelodysplastic Syndrome: Erythema Annulare Centrifugum.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Chemoradiotherapy; Drug Hypersensitivity; Erythema; Fatal Outcome; Female; Humans; Mastectomy, Radical; Sepsis | 2016 |
Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; Blood Component Transfusion; Cell Transformation, Neoplastic; Decitabine; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Propensity Score; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Kaplan-Meier Estimate; Male; Myelodysplastic Syndromes; Survival Rate; Treatment Outcome | 2016 |
[Analysis of the impact of decitabine treatment cycles on efficacy and safety in patients of myelodysplastic syndrome-refractory anemia with excess blasts].
Topics: Anemia, Refractory, with Excess of Blasts; Azacitidine; Blood Cell Count; China; Decitabine; Humans; Pancytopenia; Prevalence; Remission Induction; Retrospective Studies; Treatment Outcome | 2016 |
Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone.
Topics: Aclarubicin; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Karyotype; Male; Middle Aged; Mutation; Retrospective Studies | 2017 |
Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Benzene; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Drug Therapy, Combination; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Male; Occupational Exposure; Platelet Count; Quinolones; Thalidomide; Valproic Acid | 2009 |
Alphabet soup: RAEB, HMA, DOE, and AFOP.
Topics: Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; Biopsy; Bronchoscopy; Cryptogenic Organizing Pneumonia; Decitabine; Diagnosis, Differential; Drug Therapy, Combination; Glucocorticoids; Heart Transplantation; Humans; Male; Methylprednisolone; Middle Aged; Pulmonary Fibrosis; Tomography, X-Ray Computed | 2010 |
Acute myocarditis induced by hypomethylating agents.
Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Azacitidine; Decitabine; Humans; Middle Aged; Myocarditis; Troponin | 2011 |
Azacytidine for the treatment of myelodysplastic syndromes in the elderly.
Topics: Age Factors; Aged; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; Blood Component Transfusion; Bone Marrow; Bone Marrow Examination; Humans; Life Expectancy; Male; Monitoring, Physiologic; Myelodysplastic Syndromes; Pancytopenia; Treatment Outcome | 2011 |
Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Disease Progression; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pilot Projects; Treatment Outcome | 2012 |
5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Azacitidine; Cohort Studies; Cytogenetics; Disease Progression; Female; Humans; Male; Myelodysplastic Syndromes; Remission Induction; Treatment Outcome | 2012 |
[Effective treatment of myelodysplastic syndromes-refractory anemia with excess blasts type II by decitabine: a case report].
Topics: Anemia, Refractory, with Excess of Blasts; Azacitidine; Decitabine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2012 |
Effects of azacitidine on matrix metalloproteinase-9 in acute myeloid leukemia and myelodysplasia.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antimetabolites; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Catalysis; Cell Line, Tumor; Disease Progression; DNA Methylation; Drug Resistance, Neoplasm; Enzyme Induction; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myelomonocytic, Acute; Male; Matrix Metalloproteinase 9; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms, Second Primary; Promoter Regions, Genetic; Risk | 2013 |
Complete response of deep neutrophilic dermatosis associated with myelodysplastic syndrome to 5-azacytidine.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; Head; Humans; Male; Neck; Remission Induction; Shoulder; Skin Diseases | 2007 |
On a dramatic response of refractory anemia with excess blasts in transformation to 5-azacytidine.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Female; Humans; Leukocyte Count | 1995 |
Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome.
Topics: Acute Disease; Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Azacitidine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Pancytopenia | 1997 |
Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Anemia, Sideroblastic; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Chromosome Disorders; Decitabine; Drug Administration Schedule; Female; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Survival Rate | 2001 |